Free tool
FAERS Monitor: Segluromet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209806 or its brand name (Segluromet, Ertugliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
82
Serious
29
35% of reports
Hospitalization
16
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue11
- no adverse event8
- nausea7
- diabetic ketoacidosis6
- vomiting6
- asthenia5
- diarrhoea4
- inability to afford medication4
- blood glucose increased3
- decreased appetite3
- drug ineffective3
- inappropriate schedule of product administration3
- influenza3
- product dose omission3
- product use issue3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 6 |
| 2019 | 24 |
| 2020 | 10 |
| 2021 | 15 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,077 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inability to afford medicationSignal | 4 | 103.4 | 39.7 | 310 |
| diabetic ketoacidosisSignal | 6 | 64.1 | 29.7 | 312 |
| product dose omissionSignal | 3 | 11.8 | 3.9 | 20 |
| no adverse eventSignal | 8 | 11.3 | 5.9 | 66 |
| product dose omission issueSignal | 11 | 9.6 | 5.5 | 77 |
| influenzaSignal | 3 | 6.9 | 2.3 | 10 |
| inappropriate schedule of product administrationSignal | 3 | 4.3 | 1.4 | 5 |
| product use issueSignal | 3 | 4.1 | 1.3 | 4 |
| blood glucose increasedSignal | 3 | 4.1 | 1.3 | 4 |
| astheniaSignal | 5 | 3.4 | 1.5 | 6 |
| decreased appetite | 3 | 3.3 | 1.1 | 3 |
| vomitingSignal | 6 | 3.3 | 1.5 | 8 |
| nausea | 7 | 2.3 | 1.1 | 4 |
| diarrhoea | 4 | 1.6 | 0.6 | 0 |
| drug ineffective | 3 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.